Pembrolizumab plus Chemoradiotherapy for locally advanced Cervical Cancer - the prospective, randomized KEYNOTE-A18 Phase 3 Trial

被引：0
|
作者：
Trommer, Maike [1 ,2 ,4 ]
Gaasch, Aurelie [3 ,4 ]
Corradini, Stefanie [3 ]
机构：
[1] Univ klin Koln, Med Fak, Ctr Integrated Oncol Aachen Bonn Cologne Duesseldo, Klin & Poliklin Radioonkol, Kerpener Str 62, D-50937 Cologne, Germany
[2] Austin Hlth, Olivia Newton John Canc Wellness & Res Ctr, Dept Radiat Oncol, Melbourne, Australia
[3] Ludwig Maximilians Univ Munchen, LMU Klin, Klin & Poliklin Strahlentherapie & Radioonkol, Munich, Germany
[4] Arbeitsgruppe junge DEGRO Deutsch Gesell Radioonko, Berlin, Germany
来源：
STRAHLENTHERAPIE UND ONKOLOGIE | 2024年
关键词：
D O I：
10.1007/s00066-024-02298-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] ENGOT-CX11/GOG 3047/KEYNOTE-A18: PHASE 3 RANDOMIZED STUDY OF PEMBROLIZUMAB plus CHEMORADIOTHERAPY FOR HIGH-RISK LOCALLY ADVANCED CERVICAL CANCER
    Lorusso, D.
    Xiang, Y.
    Colombo, N.
    Coleman, R. L.
    Randall, L. M.
    Duska, L.
    Hasegawa, K.
    Nogueira-Rodrigues, A.
    Cibula, D.
    Mirza, M. R.
    You, B.
    Oaknin, A.
    Christiaens, M.
    Taskiran, C.
    Sehouli, J.
    Korach, J.
    Marth, C.
    Yamada, K.
    Puglisi, M.
    Pignata, S.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A19 - A20
  • [2] Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: A randomized, doubleblind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study
    Lorusso, D.
    Xiang, Y.
    Hasegawa, K.
    Scambia, G.
    Galves, M. H. Leiva
    Elias, P. Ramos
    Acevedo, A.
    Vizkeleti, J.
    Gomes, A. J. P. D. S.
    Mejia, F. Contreras
    Reiss, A.
    Ayhan, A.
    Lee, J. Y.
    Saevets, V.
    Zagouri, F.
    Li, K.
    Yamada, K. Ussui
    Toker, S.
    Pignata, S.
    Duska, L. R.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1279 - S1280
  • [3] EUROPEAN NETWORK FOR GYNAECOLOGICAL ONCOLOGICAL TRIAL (ENGOT)-CX11/GYNECOLOGIC ONCOLOGY GROUP (GOG) 3047/KEYNOTE-A18: PHASE 3 TRIAL OF PEMBROLIZUMAB PLUS CHEMORADIOTHERAPY IN HIGH-RISK LOCALLY ADVANCED CERVICAL CANCER
    Lorusso, D.
    Xiang, Y.
    Colombo, N.
    Coleman, R. L.
    Randall, L. M.
    Duska, L.
    Hasegawa, K.
    Nogueira-Rodrigues, A.
    Cibula, D.
    Mirza, M.
    You, B.
    Oaknin, A.
    Christiaens, M.
    Taskiran, C.
    Sehouli, J.
    Korach, J.
    Marth, C.
    Yamada, K.
    Puglisi, M.
    Pignata, S.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A43 - A44
  • [4] ENGOT-cx11/KEYNOTE-A18: A phase III, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer
    Lorusso, D.
    Xiang, Y.
    Colombo, N.
    Coleman, R.
    Randall, L.
    Duska, L.
    Hasegawa, K.
    Nogueira-Rodrigues, A.
    Cibula, D.
    Mirza, M. R.
    You, B.
    Oaknin, A.
    Christiaens, M.
    Taskiran, C.
    Sehouli, J.
    Korach, J.
    Marth, C.
    Keefe, S.
    Puglisi, M.
    Pignata, S.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S1341 - S1342
  • [5] ENGOT-CX11/GOG 3047/KEYNOTE-A18: A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF PEMBROLIZUMAB WITH CHEMORADIOTHERAPY IN PATIENTS WITH HIGH-RISK LOCALLY ADVANCED CERVICAL CANCER
    Lorusso, D.
    Colombo, N.
    Coleman, R.
    Randall, L.
    Duska, L.
    Xiang, Y.
    Hasegawa, K.
    Nogueira-Rodrigues, A.
    Cibula, D.
    Mirza, M. Raza
    You, B.
    Oaknin, A.
    Christiaens, M.
    Taskiran, C.
    Sehouli, J.
    Korach, J.
    Martin, C.
    Keefe, S.
    Puglisi, M.
    Pignata, S.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A71 - A71
  • [6] Immunotherapy in locally advanced cervical cancer: Integrating KEYNOTE-A18 into management strategies
    How, Jeffrey A.
    Jazaeri, Amir A.
    [J]. MED, 2024, 5 (06): : 487 - 489
  • [7] Pembrolizumab plus chemoradiotherapy effective in locally advanced cervical cancer
    Sidaway, Peter
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2024, 21 (06) : 402 - 402
  • [8] ENGOT-cx11/KEYNOTE-A18: A phase III, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer.
    Lorusso, Domenica
    Colombo, Nicoletta
    Coleman, Robert L.
    Randall, Leslie M.
    Duska, Linda R.
    Xiang, Yang
    Hasegawa, Kosei
    Rodrigues, Angelica Nogueira
    Cibula, David
    Mirza, Mansoor Raza
    You, Benoit
    Oaknin, Ana
    Christiaens, Melissa
    Taskiran, Cagatay
    Braicu, Elena Ioana
    Korach, Jacob
    Marth, Christian
    Keefe, Stephen Michael
    Puglisi, Martina
    Pignata, Sandro
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/ GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial
    Lorusso, Domenica
    Xiang, Yang
    Hasegawa, Kosei
    Scambia, Giovanni
    Leiva, Manuel
    Ramos-Elias, Pier
    Acevedo, Alejandro
    Sukhin, Vladyslav
    Cloven, Noelle
    Gomes, Andrea J. Pereira de Santana
    Mejia, Fernando Contreras
    Reiss, Ari
    Ayhan, Ali
    Lee, Jung-Yun
    Saevets, Valeriya
    Zagouri, Flora
    Gilbert, Lucy
    Sehouli, Jalid
    Tharavichitkul, Ekkasit
    Lindemann, Kristina
    Lazzari, Roberta
    Chang, Chih-Long
    Lampe, Rudolf
    Zhu, Hong
    Oaknin, Ana
    Christiaens, Melissa
    Polterauer, Stephan
    Usami, Tomoka
    Li, Kan
    Yamada, Karin
    Toker, Sarper
    Keefe, Stephen M.
    Pignata, Sandro
    Duska, Linda R.
    [J]. LANCET, 2024, 403 (10434): : 1341 - 1350
  • [10] Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trial
    Rodrigues, Manuel
    Vanoni, Giulia
    Loap, Pierre
    Dubot, Coraline
    Timperi, Eleonora
    Minsat, Mathieu
    Bazire, Louis
    Durdux, Catherine
    Fourchotte, Virginie
    Laas, Enora
    Pouget, Nicolas
    Castel-Ajgal, Zahra
    Marret, Gregoire
    Lesage, Laetitia
    Meseure, Didier
    Vincent-Salomon, Anne
    Lecompte, Lolita
    Servant, Nicolas
    Vacher, Sophie
    Bieche, Ivan
    Malhaire, Caroline
    Huchet, Virginie
    Champion, Laurence
    Kamal, Maud
    Amigorena, Sebastian
    Lantz, Olivier
    Chevrier, Marion
    Romano, Emanuela
    [J]. NATURE COMMUNICATIONS, 2023, 14 (01)
12345